The company Arterial Remodeling Technologies (“ART”) Privately owned, has announced that it treatment approved for the CE marking of its drug-free bioresorbable stent the next generation received from coronary arteries. The CE certification is the result of extensive pre-clinical studies, including a three-year follow-up period, as well as supportive clinical outcomes of coronary renowned centers such as the Hôpital Européen Georges Pompidou in Paris and researchers such as Dr Jean Fajadet at the Clinique Pasteur in Toulouse.
The technology developed by ART bioresorbable advanced restraint should support the vessel treated temporarily effective but disintegrate after three months and adjust their primary mechanical support function. Three months is generally considered the required time period in which the healing process stabilizes the artery enough. Furthermore, the support designed that it allows complete absorption of the polymer within 24 months. The drug-free, bioresorbable support of ART is particularly suitable for treating larger lumen coronary lesions.
“The receipt of CE mark for our bioresorbable stent is a significant milestone for ART, especially since we are striving to develop the technology for the treatment of coronary artery disease and peripheral vascular disease,” said Machiel van der Leest, CEO ART. “We are very pleased with the clinical performance of the bioresorbable stent.”
As part of an agreement entered into in March 2014 agreement between Terumo and ART Terumo acquired an exclusive option for the acquisition of technology of drug-eluting bioabsorbable stent. The technology developed by ART bioresorbable support with CE marking serves as a platform for the next generation of drug-eluting bioabsorbable stents, which are developed by Terumo. Coronary artery disease is the most common form of heart disease and a leading cause of death in men and women.
Other indications, such as the use of drug-eluting bioabsorbable stent for peripheral vascular disease, developed by Vascular bioresorbable Technologies (“VBT”) under an exclusive license agreement for the development of the platform technology of ART.
Arterial Remodeling Technologies ( www.art-stent.com ), a privately held French company develops bioresorbable polymer stents, promote the natural reconstruction of an injured artery. The company’s technology is based on the intellectual property of three prestigious institutions, namely the Cleveland Clinic, the French national research institute CNRS (Centre National de Recherche Scientifique) and the Descartes University in Paris. The company’s investors include Bpifrance, Idinvest Partners, Turenne Capital Partners, Matignon Investissement et Gestion, Vesale Partners and Amundi Asset Management.
The original language in which the original text of this announcement is the official, authoritative version. Translations are provided as an accommodation. Only the language version, which was published in the original is valid. Equal to Thus Translations with the original language of publication.
View Original version on businesswire.com: http://www.businesswire.com/news / home / 20150518005460 / de /
No comments:
Post a Comment